The role of tumor markers in office urology for screening, diagnosis and follow up of bladder cancer;El papel de los marcadores tumorales en la consulta de urología para el screening, diagnóstico y seguimiento del cancer de vejiga

Actas Urologicas Espanolas

Volumn 27, Issue 2, 2003, Pages 110-116

  Lorenzo Gomez M F ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Departmento of Urology   (United States)

Author keywords

Bladder; Diagnosis; Markers; Screening; Tumor

Indexed keywords

TUMOR MARKER;

ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CANCER SCREENING; CYSTOSCOPY; CYTOLOGY; FOLLOW UP; HUMAN; MEDLINE; SENSITIVITY AND SPECIFICITY; TRANSITIONAL CELL CARCINOMA; URINALYSIS;

EID: 0037304169     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0210-4806(03)72888-5     Document Type: Article

References (39)

1. EDWARD M, MESSING, CATALONA W.: Bladder cancer. Campbell's Urology. Seventh Edition 1998; 3: 2.329-2.410.
2. PATTON SE, CRAIG-HALL M, OZEN H.: Bladder cancer. Curr Opin Oncol 2002; 14 (3): 265-272.
3. PISANI P, PARKIN DM, FERLAY J.: Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 1993; 55: 891-903.
4. NAWROCKI S, SKACEL T, SKONECZNA I.: Pharmacotherapy of bladder cancer - practice and prospects. Expert Opin Pharmacother 2002; 3 (6): 671-679.
5. MESSING EM, VALENCOURT A.: Hematuria screening for bladder cancer. J Occup Med 1990; 32: 838.
6. ZEEGERS MP, GOLDBOHM RA, VAN DEN BRANDT PA.: A prospective study on active and environmental tobacco smoking and bladder cancer risk. Cancer Causes Control 2002; 13 (1): 83-90.
7. SANKARANARAYANAN R.: Integration of cost-efective early detection programs into the health services of developing countries. Cancer 2000; 89 (3): 475-481.
8. ACS News Today: Scientistics confirm cancer risk from second-hand smoke increases cancer risk by one-fifth. Artcle date: 2002/07/09.
9. rd, YIN S, MA Z, BONNER RB, BI W, RAO JY, ZANG M, ZHENG Q, BANE B, ASAL N, LI G, FENG P, HURST RE, WANG W.: Biomarker risk assessment and bladder cancer detection in a cohort exposed to benzidine. J Natl Cancer Inst 2001; 93 (6): 427-436.
10. WOLF HK, STOBER C, HOHENFELLNER R, LEISSNER J.: Prognostic value of p53, p21/WAF1, Bcl-2, Bax, Bak and Ki-67 immunoreactivity in pT1G3 urothelial bladder carcinomas. Tumor Biol 2001; 22: 328-336.
11. WIENER HG, MIAN C, HAITEL A, PYCHA A, SCHATZL G, MARBERGER M.: Can urine boung diagnostic tests replace cystoscopy in the management of bladder cancer? J Urol 1999; 159: 1.876.
12. LANDMAN J, CHANG Y, KAVALER E, DROLLER MJ, LIU BC.: Sensitivity and specificity of NMP22, telomerase, and BTA in the detection of human bladder cancer. Urology 1998; 52 (3): 398-402.
13. KOSHIKAVA T, LEYH H, SCHENCK U.: Difficulties in evaluating urinary specimens after local mitomycin therapy of bladder cancer. Diagn Cytopathol 1989; 5: 117.
14. DE VERE, WHITE R.: Editorial comment. J Urol 2002; 167: 83.
15. LOKESHWAR VB, OBEK C, PHAM HT, WEI D, YOUNG MJ, DUNCAN RC, SOLOWAY MS, BLOCK NL.: Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade. J Urol 2000; 163 (1): 348-356.
16. LOKESHWAR V, SOLOWAY MS.: Letters to the Editor. J Urol 2002; 167: 1.405-1.408.
17. SAROSDY MF, HUDSON MA, ELLIS MJ, SOLOWAY MS, DE VERE WHITE R, SHEINFELD J, JAROWENKO MV, SCHELLHAMMER PF, SCHERVISH EW, PATEL JV, CHODAK GW, LAMM DL, JOHNSON RD, HENDERSON M, ADAMS G, BLUMENSTEIN BA, THOELKE KR, PFALZGRAF RD, MURCHISON HA, BRUNELLE SL: Improved detection of recurrent bladder cancer using the Bard BTA stat test. Urology 1997; 50 (3): 349-353.
18. NASUTI JF, GOMELLA LG, ISMIAL M, BIBBO M.: Utility of the BTAstat test kit for bladder cancer screening. Diagn Cytopathol 1999; 21: 27.
19. LEYH H, MARBERGER M, CONORT P, STERNBERG C, PANSADORO V, PAGANO F, BASSI P, BOCCON-GIBOD L, RAVERY V, TREIBER U, ISHAK L: Comparison of BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer. Eur Urol 1999; 35 (1): 52-56.
20. BOMAN H, HEDELIN H, HOLMANG S.: Four bladder tumor markers have a disppointingly low sensitivity for small size and low grade recurrence. J Urol 2002; 167: 80-83.
21. OGE O, ATSU N, KENDI S, OZEN H.: Evaluation of nuclear matrix protein 22 (NMP22) as a tumor marker in the detection of bladder cancer. Int Urol Nephrol 2001; 32 (3): 367-370.
22. OHTANI M, IWASAKI A, SHIRAIWA H: Urinary tumor marker for urothelial cancer. Gan To Kagaku Ryoho 2001; 28 (12): 1.933-1.937.
23. LOKESHWAR VB, SOLOWAY M.: Current bladder tumor test: does their projected utility fulfill clinical necessity? J Urol 165 (4): 1.067-1.077.
24. ÁLVAREZ-KINDELAN J, LÓPEZ-BELTRÁN A, REQUENA-TAPIA MJ.: Biología molecular en el cáncer vesical. Actas Urol Esp 2000; 24 (8): 604-625.
25. rd, FRADET Y, RAO JY, MIN KW, HURST RE.: Bladder cancer risk assessment with quantitative fluorescence image analysis of tumor markers in exfoliated bladder cells. Cancer 1993; 72 (8): 2.461-2.469.
26. KONETY BR, GETZENBERG RH.: Urine based markers of urological malignancy. J Urol 2001; 165 (2): 600-611.
27. VRIESEMA JL, ATSMA F, KIEMENEY LA, PEELEN WP, WITJES JA, SCHALKEN JA.: Diagnostic efficacy of the ImmunoCyt test to detect superficial bladder cancer recurrence. Urology 2001; 58 (3): 367-371.
28. rd: Characterization of the DD23 tumor-associated antigen for bladder cancer detection and recurrence monitoring. Marker Network for bladder cancer. Cancer Epidemiol Biomarkers Prevent 1996; 5 (12): 971-978.
29. SÁNCHEZ-CARBAYO M, URRUTIA M, GONZÁLEZ DE BUITRAGO JM, NAVAJO JA.: Utility of serial urinary tumor markers to individualize intervals between cystoscopies in the monitoring of patients with bladder carcinoma. Cancer 2001; 92 (11): 2.820-2.828.
30. SÁNCHEZ-CARBAYO M, CIUDAD J, URRUTIA M, MAVAJO JA, ORFAO A.: Diagnostic performance of the urinary bladder carcinoma antigen ELISA test and a multiparametric DNA/cytokeratin flowcytometry in urine voided samples from patients with bladder carcinoma. Cancer 2001; 92 (11): 2.811-2.819.
31. PARIENTE JL, BORDENAVE L, MICHEL P, LATAPIE MJ, DUCASSON D, LE GUILLON M: Initial evaluation of CYFRA 21-1 diagnostic performances as a urinary marker in bladder transitional cell carcinoma. J Urol 1997; 158 (2): 338-341.
32. MADY EA.: Cytoketarins as serum markers in egyptian bladder cancer. A comparison of CYFRA 21-1, TPA and TPS. Int J Biol Markers 2001; 16 (2): 130-135.
33. rd, FRIAS-HIDVEGI D, MCVARY K, BACUS JW.: Cytology, flow cytometry, image analysis and interphase cytogenetics by fluorescence in situ hybridization in the diagnosis of transitional cell carcinoma in bladder washes: a comparative study. Diag Cytopathol 1995; 13 (3): 214-223.
34. WITJES JA, VAN DER POEL HG, VAN BALKEN MR, DEBRUYNE FM, SCHALKEN JA: Urinary NMP22 and kariometry in the diagnosis and follow up of patients with superficial bladder cancer. Eur Urol 1998; 33 (4): 387-391.
35. YOSHIDA K, SUGINO T, TAHARA H, WOODMAN A, BOLODEKU J, NARGUND V, FELLOW SG, GOODISON S, TAHARA E, TARIN D.: Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection exfoliated cancer cells in urine. Cancer 1997; 79 (2): 362-369.
36. MULLER M, KRAUSE H, HEICAPPELL R.: Comparison of human telomerase activity in urine for diagnosis of bladder cancer. Clin Cancer Res 1998; 4: 1.949.
37. MIYAKE H, HARA I, GOHJI K et al.: Urinary cytology and competitive reverse transcriptase-polimerase chain reaction analysis of a specific CD44 variant to detect and monitor bladder cancer. J Urol 1998; 160: 2.004.
38. LOKESHWAR VB, OBEK C, SOLOWAY MS, BLOCK NL: Tumor-associated hyaluronic acid: a new sensitive and specific urine marker for bladder cancer. Cancer Res 1997; 57 (4): 773-777.
39. PHAM HT, BLOCK NL, LOKESHWAR VB.: Tumor-derived hyaluronidase: a diagnostic urine marker for highgrade bladder cancer. Cancer Res 1997; 57 (4): 778-783.